Possible involvement of enhanced arginase activity due to up-regulated arginases and decreased hydroxyarginine in accelerating intimal hyperplasia with hyperglycemia

被引:14
作者
Ishizaka, Mihoko
Nagai, Akiko
Iwanaga, Mioko
Imamura, Masatoshi
Azuma, Hiroshi
机构
[1] Tokyo Med & Dent Univ, Grad Sch, Inst Biomat & Bioengn, Dept Biosyst Regulat,Chiyoda Ku, Tokyo 1010062, Japan
[2] Tokyo Med & Dent Univ, Grad Sch, Inst Biomat & Bioengn, Dept Inorgan Mat,Chiyoda Ku, Tokyo 1010062, Japan
关键词
intimal hyperplasia; Hyperglycemia; arginase I and II; endogenous NOS inhibitors; DDAH; hydroxyarginine;
D O I
10.1016/j.vph.2007.08.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The present study was designed to investigate the roles of enhanced arginase activity due to up-regulated arginases and the decreased hydroxyarginine for accelerating intimal hyperplasia with hyperglycemia. Thirteen weeks after injection of alloxan or physiological saline, endothelial denudation of the carotid artery was performed to induce intimal hyperplasia. The intimal hyperplasia occurred on 4 weeks following denudation was significantly accelerated by hyperglycemia. The method to measure L-arginine, endogenous NOS inhibitors such as monomethylarginine and asymmetric dimethylarginine, and hydroxyarginine as an intermediate of NO production simultaneously was established with the aid of high-performance liquid chromatography. In hyperglycemia group, the impaired cyclic GMP production as an indicator of NO production in endothelial cells was accompanied by the enhanced arginase activity together with increased expression of arginase I and H proteins, accumulated endogenous NOS inhibitors, reduced concentration of hydroxyarginine, and decreased DDAH activity in endothelial cells. However, NOS activity per se remained unchanged in the hyperglycemia group. Authentic hydroxyarginine inhibited arginase activity in a concentration-dependent manner. The inhibition of arginase with hydroxyarginine at a reduced concentration with hyperglycemia became significantly lower than that for the control. These results suggest that the accelerated intimal hyperplasia with hyperglycemia is closely related to the impaired NO production in endothelial cells, which results from accumulation of endogenous NOS inhibitors and accelerated arginase activity together with up-regulation of arginase I and 11 proteins. Decreased DDAH activity would bring about the accumulation of endogenous NOS inhibitors. Furthermore, reduced concentration of hydroxyarginine with hyperglycemia possibly results in an enhanced arginase activity in vivo, implicating partly in the impairment of NO production. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:272 / 280
页数:9
相关论文
共 35 条
[1]   RABBIT AORTIC SMOOTH-MUSCLE CELL-CULTURE - A MODEL FOR THE PHARMACOLOGICAL STUDY OF DIABETES-INDUCED ALTERATIONS IN CELL-PROLIFERATION [J].
ALIPUI, C ;
TENNER, TE ;
RAMOS, K .
JOURNAL OF PHARMACOLOGICAL METHODS, 1991, 26 (03) :211-222
[2]   ACCUMULATION OF ENDOGENOUS INHIBITORS FOR NITRIC-OXIDE SYNTHESIS AND DECREASED CONTENT OF L-ARGININE IN REGENERATED ENDOTHELIAL-CELLS [J].
AZUMA, H ;
SATO, J ;
HAMASAKI, H ;
SUGIMOTO, A ;
ISOTANI, E ;
OBAYASHI, S .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 115 (06) :1001-1004
[3]   PREVENTION OF INTIMAL THICKENING AFTER ENDOTHELIAL REMOVAL BY A NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST, LOSARTAN [J].
AZUMA, H ;
NIIMI, Y ;
HAMASAKI, H .
BRITISH JOURNAL OF PHARMACOLOGY, 1992, 106 (03) :665-671
[4]   ENDOTHELIUM-DEPENDENT INHIBITION OF PLATELET-AGGREGATION [J].
AZUMA, H ;
ISHIKAWA, M ;
SEKIZAKI, S .
BRITISH JOURNAL OF PHARMACOLOGY, 1986, 88 (02) :411-415
[5]   ROLE OF ENDOTHELIN-1 IN NEOINTIMA FORMATION AFTER ENDOTHELIAL REMOVAL IN RABBIT CAROTID ARTERIES [J].
AZUMA, H ;
HAMASAKI, H ;
NIIMI, Y ;
TERADA, T ;
MATSUBARA, O .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1994, 267 (06) :H2259-H2267
[6]   Endogenous nitric oxide synthase inhibitors in endothelial cells, endothelin-1 within the vessel wall, and intimal hyperplasia in perimenopausal human uterine arteries [J].
Beppu, M ;
Obayashi, S ;
Aso, T ;
Goto, M ;
Azuma, H .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2002, 39 (02) :192-200
[7]  
Blantz RC, 2000, ACTA PHYSIOL SCAND, V168, P21
[8]   Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits [J].
BodeBoger, SM ;
Boger, RH ;
Kienke, S ;
Junker, W ;
Frolich, JC .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 219 (02) :598-603
[9]   Asymmetric dimethylarginine (ADMA):: A novel risk factor for endothelial dysfunction -: Its role in hypercholesterolemia [J].
Böger, RH ;
Bode-Böger, SM ;
Szuba, A ;
Tsao, PS ;
Chan, JR ;
Tangphao, O ;
Blaschke, TF ;
Cooke, JP .
CIRCULATION, 1998, 98 (18) :1842-1847
[10]   The clinical pharmacology of L-arginine [J].
Böger, RH ;
Bode-Böger, SM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 :79-99